Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

BACKGROUND: We evaluated Aβ misfolding in combination with Aβ(42/40) ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) in individuals with subjective cognitive decline (SCD). METHODS: Baseline plasma samples (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Stockmann, Julia, Verberk, Inge M. W., Timmesfeld, Nina, Denz, Robin, Budde, Brian, Lange-Leifhelm, Julia, Scheltens, Philip, van der Flier, Wiesje M., Nabers, Andreas, Teunissen, Charlotte E., Gerwert, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761044/
https://www.ncbi.nlm.nih.gov/pubmed/33357241
http://dx.doi.org/10.1186/s13195-020-00738-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761044/
https://www.ncbi.nlm.nih.gov/pubmed/33357241
http://dx.doi.org/10.1186/s13195-020-00738-8

Ejemplares similares